Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Carolina Soares Viana de Oliveira"'
Autor:
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101917- (2023)
Summary: Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with mic
Externí odkaz:
https://doaj.org/article/607bb200b67a4b90be60f4ef3e49d300
Autor:
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Timothy Larson, Allen Lee Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, David R. D'Adamo, Amy Hammell, Neelesh Sharma, Sabine Coppieters, Anke Schulz, Henrik Seidel, Matthias Herpers, Carolina Soares Viana de Oliveira, Andrew Scott Paulson, Ying A. Wang
Publikováno v:
Journal of Clinical Oncology. 40:89-89
89 Background: Combination treatment with regorafenib (80–120 mg/day, PO, 3 wks on/1 wk off) plus nivolumab (480 mg IV Q4W) showed manageable safety but modest efficacy in a phase 2 study of 70 pts from North America with pMMR/MSS chemotherapy-resi
Autor:
Sabine Coppieters, David Z. Chang, Carolina Soares Viana de Oliveira, Timothy S. Larson, Matthias Herpers, Kanwal Pratap Singh Raghav, Johanna C. Bendell, David Cosgrove, Neelesh Sharma, Ying A. Wang, Joseph A. Fiorillo, Marwan Fakih, Allen Lee Cohn, Timothy K. Huyck, Andrew Scott Paulson, David D'Adamo, Lawrence Garbo, Shruthi Ravimohan, Von Potter
Publikováno v:
Journal of Clinical Oncology. 39:3560-3560
3560 Background: The role of immunotherapy in the treatment of pMMR/MSS metastatic CRC is not established. A Japanese phase 1b trial in this setting showed the combination of regorafenib (multikinase inhibitor with immunomodulatory activity) plus niv